Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis

Danielle Tartar, Lorinda Chung, David F. Fiorentino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Autoimmune connective tissue diseases, including dermatomyositis and systemic sclerosis, have a heterogeneous clinical presentation and prognosis; moreover, their clinical features are often incomplete and overlap with other rheumatic disorders, which can make diagnosis and prognostic stratification challenging. Specific autoantibodies have been associated with certain clinical findings as well as prognostic implications, and many new associations have been made over the last decade. Although patient populations manifest considerable heterogeneity, autoantibodies can be used to help predict clinical features, prognosis, and response to therapy. In this review, the clinical and prognostic implications associated with disease-specific autoantibodies in dermatomyositis and scleroderma are summarized with an emphasis on how the clinician can use this information for patient care.

Original languageEnglish (US)
Pages (from-to)508-524
Number of pages17
JournalClinics in Dermatology
Volume36
Issue number4
DOIs
StatePublished - Jul 1 2018

Fingerprint

Dermatomyositis
Systemic Scleroderma
Autoantibodies
Connective Tissue Diseases
Patient Care
Population
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. / Tartar, Danielle; Chung, Lorinda; Fiorentino, David F.

In: Clinics in Dermatology, Vol. 36, No. 4, 01.07.2018, p. 508-524.

Research output: Contribution to journalArticle

Tartar, Danielle ; Chung, Lorinda ; Fiorentino, David F. / Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. In: Clinics in Dermatology. 2018 ; Vol. 36, No. 4. pp. 508-524.
@article{1f7fe71079f34fa297400bb66baa277a,
title = "Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis",
abstract = "Autoimmune connective tissue diseases, including dermatomyositis and systemic sclerosis, have a heterogeneous clinical presentation and prognosis; moreover, their clinical features are often incomplete and overlap with other rheumatic disorders, which can make diagnosis and prognostic stratification challenging. Specific autoantibodies have been associated with certain clinical findings as well as prognostic implications, and many new associations have been made over the last decade. Although patient populations manifest considerable heterogeneity, autoantibodies can be used to help predict clinical features, prognosis, and response to therapy. In this review, the clinical and prognostic implications associated with disease-specific autoantibodies in dermatomyositis and scleroderma are summarized with an emphasis on how the clinician can use this information for patient care.",
author = "Danielle Tartar and Lorinda Chung and Fiorentino, {David F.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.clindermatol.2018.04.008",
language = "English (US)",
volume = "36",
pages = "508--524",
journal = "Clinics in Dermatology",
issn = "0738-081X",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis

AU - Tartar, Danielle

AU - Chung, Lorinda

AU - Fiorentino, David F.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Autoimmune connective tissue diseases, including dermatomyositis and systemic sclerosis, have a heterogeneous clinical presentation and prognosis; moreover, their clinical features are often incomplete and overlap with other rheumatic disorders, which can make diagnosis and prognostic stratification challenging. Specific autoantibodies have been associated with certain clinical findings as well as prognostic implications, and many new associations have been made over the last decade. Although patient populations manifest considerable heterogeneity, autoantibodies can be used to help predict clinical features, prognosis, and response to therapy. In this review, the clinical and prognostic implications associated with disease-specific autoantibodies in dermatomyositis and scleroderma are summarized with an emphasis on how the clinician can use this information for patient care.

AB - Autoimmune connective tissue diseases, including dermatomyositis and systemic sclerosis, have a heterogeneous clinical presentation and prognosis; moreover, their clinical features are often incomplete and overlap with other rheumatic disorders, which can make diagnosis and prognostic stratification challenging. Specific autoantibodies have been associated with certain clinical findings as well as prognostic implications, and many new associations have been made over the last decade. Although patient populations manifest considerable heterogeneity, autoantibodies can be used to help predict clinical features, prognosis, and response to therapy. In this review, the clinical and prognostic implications associated with disease-specific autoantibodies in dermatomyositis and scleroderma are summarized with an emphasis on how the clinician can use this information for patient care.

UR - http://www.scopus.com/inward/record.url?scp=85049463043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049463043&partnerID=8YFLogxK

U2 - 10.1016/j.clindermatol.2018.04.008

DO - 10.1016/j.clindermatol.2018.04.008

M3 - Article

C2 - 30047434

AN - SCOPUS:85049463043

VL - 36

SP - 508

EP - 524

JO - Clinics in Dermatology

JF - Clinics in Dermatology

SN - 0738-081X

IS - 4

ER -